Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 5.86 is 52% above its 5-year average of 3.86, around the middle of its 5-year range (0.26–13.78).
As of the fiscal period ended Tuesday, June 30, 2026. 18.42% above its 12-month average of 4.95.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 5.86.
QUICK RATIO (ACID-TEST)
5.86
QUICK RATIO (ACID-TEST) AVG TTM
4.95
QUICK RATIO (ACID-TEST) AVG 3Y
2.91
QUICK RATIO (ACID-TEST) AVG 5Y
3.86
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+18.42%
CURRENT VS 3Y AVG
+101.61%
CURRENT VS 5Y AVG
+51.95%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
2.99
median of 631 covered companies
CURRENT VS SECTOR MEDIAN
+96.15%
vs the sector median at left
CNS Pharmaceuticals, Inc.
Market Cap
$7.83M
Quick Ratio (Acid-Test)
5.86
TTM Avg
4.95
3Y Avg
2.91
5Y Avg
3.86
Market Cap
$7.91M
Quick Ratio (Acid-Test)
2.61
TTM Avg
2.11
3Y Avg
2.42
5Y Avg
2.17
Market Cap
$7.98M
Quick Ratio (Acid-Test)
-71.42
TTM Avg
0.41
3Y Avg
1.44
5Y Avg
1.15
Market Cap
$8.00M
Quick Ratio (Acid-Test)
7.10
TTM Avg
3.48
3Y Avg
3.44
5Y Avg
4.75
Market Cap
$8.12M
Quick Ratio (Acid-Test)
13.55
TTM Avg
6.32
3Y Avg
6.80
5Y Avg
6.83
Market Cap
$8.24M
Quick Ratio (Acid-Test)
0.10
TTM Avg
0.10
3Y Avg
0.10
5Y Avg
0.10
Market Cap
$7.33M
Quick Ratio (Acid-Test)
2.63
TTM Avg
4.46
3Y Avg
3.65
5Y Avg
4.69
Market Cap
$7.33M
Quick Ratio (Acid-Test)
1.37
TTM Avg
3.92
3Y Avg
4.12
5Y Avg
3.73
Market Cap
$7.20M
Quick Ratio (Acid-Test)
45.95
TTM Avg
58.73
3Y Avg
40.89
5Y Avg
40.89
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CNS Pharmaceuticals, Inc. (CNSP) | $7.83M | 5.86 | 4.95 | 2.91 | 3.86 |
| GT Biopharma, Inc. (GTBP)vs › | $7.91M | 2.61 | 2.11 | 2.42 | 2.17 |
| HeartSciences Inc. (HSCS)vs › | $7.98M | -71.42 | 0.41 | 1.44 | 1.15 |
| ENDRA Life Sciences Inc. (NDRA)vs › | $8.00M | 7.10 | 3.48 | 3.44 | 4.75 |
| Aprea Therapeutics, Inc. (APRE)vs › | $8.12M | 13.55 | 6.32 | 6.80 | 6.83 |
| DataMEDS AI, Inc. (MEDS)vs › | $8.24M | 0.10 | 0.10 | 0.10 | 0.10 |
| Longeveron Inc. (LGVN)vs › | $7.33M | 2.63 | 4.46 | 3.65 | 4.69 |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.33M | 1.37 | 3.92 | 4.12 | 3.73 |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.20M | 45.95 | 58.73 | 40.89 | 40.89 |
| KALA BIO, Inc. (KALA)vs › | $7.22M | 6.88 | 3.46 | 4.15 | 4.53 |
Quick Ratio
5.86
Excludes inventory
Current Ratio
5.86
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 5.86 |
| 2026-03-31 | 0.88 |
| 2025-12-31 | 1.98 |
| 2025-09-30 | 5.81 |
| 2025-06-30 | 10.22 |
| 2025-03-31 | 4.94 |
| 2024-12-31 | 3.43 |
| 2024-09-30 | 1.82 |
| 2024-06-30 | 0.32 |
| 2024-03-31 | 0.26 |
| 2023-12-31 | 0.26 |
| 2023-09-30 | 0.51 |
| 2023-06-30 | 1.52 |
| 2023-03-31 | 1.78 |
| 2022-12-31 | 2.55 |
| 2022-09-30 | 6.99 |
| 2022-06-30 | 12.34 |
| 2022-03-31 | 13.78 |
| 2021-12-31 | 3.50 |
| 2021-09-30 | 4.63 |
| 2021-06-30 | 7.58 |
| 2021-03-31 | 6.72 |
| 2020-12-31 | 8.13 |
| 2020-09-30 | 4.93 |
| 2020-06-30 | 15.14 |
| 2020-03-31 | 18.42 |
| 2019-12-31 | 25.38 |
| 2019-09-30 | 0.99 |
| 2019-06-30 | 1.27 |
| 2019-03-31 | 0.35 |
| 2018-12-31 | 0.48 |
| 2018-09-30 | 0.00 |
| 2018-06-30 | 0.75 |
| 2018-03-31 | 1.16 |
